<DOC>
	<DOCNO>NCT01155362</DOCNO>
	<brief_summary>The primary objective study estimate treatment effect 3 different dos PDA001 versus placebo subject moderate-to-severe Crohn 's Disease . The secondary objective study assess safety tolerability PDA001 versus placebo above-mentioned patient population .</brief_summary>
	<brief_title>A Multi-Center Study Evaluate Safety Efficacy Intravenous Infusion Human Placenta-Derived Cells ( PDA001 ) Treatment Adults With Moderate-to-Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Males female age 1875 year 2 . Understand voluntarily sign informed consent 3 . Able adhere study visit schedule protocol requirement 4 . Minimum weight 50 kg 5 . A female childbearing potential ( FCBP ) â€  must negative urine pregnancy test screening ( Visit 1 ) immediately prior dos IP . In addition , sexually active FCBP must agree use two adequate form contraception method duration study followup period . A FCBP must agree pregnancy test least every 4 week study . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage reproductive sexual activity FCBP duration study followup period . 6 . Subject must inflammatory CD 6 month prior treatment confirmation ongoing disease activity colonoscopy ( method ) screen 7 . Subject must CDAI score &gt; 220 &lt; 450 assessed Visit 1 Visit 2 8 . The Subject must fail , i.e. , inadequate response lose response ( recurrence symptom ) agent , document intolerance agent time 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study A female childbearing potential sexually mature woman : 1. undergone hysterectomy bilateral oophorectomy 2. naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Human Placenta-Derived Cells Treatment Moderate-to-Severe Crohn 's Disease</keyword>
</DOC>